Clinical Trial Update: A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the tolerability of BI 770371 in people with compensated cirrhosis due to MASH has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• BI 770371

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH) | Phase 2 | Status: COMPLETED